AstraZeneca shareholders approved a direct listing of the drugmaker’s shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.<\/p>\n
The drugmaker said 99.36% of votes cast in a general meeting favoured the proposal. The company needed at least 75% of votes for the resolution to pass.<\/p>\n
AstraZeneca, London’s most valuable company, outlined plans for a much-anticipated U.S. direct listing in September, replacing its existing American depositary receipts on the Nasdaq with ordinary shares on the NYSE, while retaining its London and Stockholm listings.<\/p>\n
The U.S. market accounts for more than 40% of AstraZeneca’s revenue, making it critical to CEO Pascal Soriot’s growth strategy and future outlook amid mounting political scrutiny.<\/p>\n
AstraZeneca Chair Michel Demare said in a statement that the shareholder vote in favour of the board’s proposal showed strong investor confidence in the company’s move to streamline its listing across London, Stockholm and New York.<\/p>\n
He said the harmonised listing structure would give AstraZeneca greater flexibility to tap global capital markets, particularly in the U.S., as it continues to expand in high-growth regions.<\/p>\n
While analysts and policymakers had expressed relief that the Anglo-Swedish drugmaker’s plans did not include ditching its London listing altogether, there are still concerns that the move could prompt other large companies to follow suit.<\/p>\n
The direct listing on the NYSE is expected to go live on February 2, 2026.<\/p>\n","protected":false},"excerpt":{"rendered":"
AstraZeneca shareholders approved a direct listing of the drugmaker’s shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool. The drugmaker said 99.36% of votes cast in a general meeting favoured the proposal. The company needed at least 75% of votes for the resolution to pass. AstraZeneca, London’s […]<\/p>\n","protected":false},"author":2,"featured_media":2430,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[755],"class_list":{"0":"post-2429","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sitefansalaran-industry-news","8":"tag-astrazeneca-wins-shareholder-backing-for-nyse-listing-in-us-pivot"},"yoast_head":"\n